Publication date: Available online 21 June 2017
Source:Vaccine
Author(s): Sami L. Gottlieb, Birgitte Giersing, Marie-Claude Boily, Harrell Chesson, Katharine J. Looker, Joshua Schiffer, Ian Spicknall, Raymond Hutubessy, Nathalie Broutet
Development of a vaccine against herpes simplex virus (HSV) is an important goal for global sexual and reproductive health. In order to more precisely define the health and economic burden of HSV infection and the theoretical impact and cost-effectiveness of an HSV vaccine, in 2015 the World Health Organization convened an expert consultation meeting on HSV vaccine impact modelling. The experts reviewed existing model-based estimates and dynamic models of HSV infection to outline critical future modelling needs to inform development of a comprehensive business case and preferred product characteristics for an HSV vaccine. This article summarizes key findings and discussions from the meeting on modelling needs related to HSV burden, costs, and vaccine impact, essential data needs to carry out those models, and important model components and parameters.
from α via xlomafota.13 on Inoreader http://ift.tt/2sTVhGk
via IFTTT
Ιατρική Αλέξανδρος Γ. Σφακιανάκης,Αναπαύσεως 5 Άγιος Νικόλαος 72100 Κρήτη 00302841026182 Medical Articles by Alexandros G.Sfakianakis PhD,Anapafseos 5 Agios Nikolaos 72100 Crete Greece 00306932607174
! # Ola via Alexandros G.Sfakianakis on Inoreader
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου